Monograph Details
|
|
Infections & Infestations
> Malaria
|
|
ARALEN |
| Manufacturer |
|
Sanofi Aventis |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Aminoquinoline. |
| Generic Name |
|
Chloroquine phosphate 500mg; tabs. |
| Indications |
|
Suppression and treatment of susceptible malaria. |
| Children |
|
Suppression: 8.35mg/kg (max 500mg) once every 7 days. Treatment: 16.7mg/kg (max 1g) once, then 8.35mg/kg (max 500mg) 6, 24 and 36 hrs after 1st dose. |
| Adults |
|
Suppression: 500mg once every 7 days. Treatment: 1g once, then 500mg 6–8 hrs later; then 500mg once daily for next 2 days. Low body wt: use children's dose. |
| Contraindications |
|
Retinal or visual field changes. |
| Precautions |
|
Suppression: start 2 wks before and continue for 8 wks after trip. Hepatic or auditory dysfunction. Alcoholism. Psoriasis. Porphyria. Seizure disorders. G6PD deficiency. Discontinue if hematologic, visual disorders or ototoxicity occurs. Monitor CBC, reflexes, vision in long-term use. Elderly. Children. Pregnancy (use adequate contraception in endemic areas). Nursing mothers: not recommended. |
| Interactions |
|
Avoid cimetidine. Separate ampicillin dose by 2 hours; dosing of antacids, kaolin by 4 hours. Potentiates cyclosporine (monitor). Caution with hepatotoxic drugs. |
| Adverse Reactions |
|
Retinopathy, headache, pruritus, photosensitivity, GI or CNS disturbances (eg, seizures, psychosis, tinnitus, visual changes) blood dyscrasias, neuromyopathy, cardiomyopathy. |
| How Supplied |
|
Tabs—25 |
|
|
|
|
